Back
Our Progress in 2023 and Plans for 2024 - Open Philanthropy (via Coefficient Giving)
webCredibility Rating
4/5
High(4)High quality. Established institution or organization with editorial oversight and accountability.
Rating inherited from publication venue: Coefficient Giving
Annual review from Open Philanthropy (now Coefficient Giving) summarizing 2023 grantmaking impact and 2024 strategy, relevant for understanding major AI safety funding trends and philanthropic coordination in the field.
Metadata
Importance: 42/100organizational reportnews
Summary
Alexander Berger reviews Open Philanthropy's major achievements in 2023, including supporting the R21 malaria vaccine approval and funding key AI safety initiatives, while outlining plans for 2024. The report highlights OP's rapid growth to ~110 staff and over $750M in annual giving, and details contributions to landmark AI policy events including the UK AI Safety Summit and US executive order on AI.
Key Points
- •Open Philanthropy nearly doubled annual giving to >$750M and grew to ~110 staff, adding five new program areas in recent years.
- •OP-funded clinical trials contributed to WHO recommending the R21 malaria vaccine, expected to benefit all at-risk children globally.
- •AI safety grantees contributed to the UK AI Safety Summit, US executive order on AI, and the first US-China International Dialogue on AI Safety.
- •Center for AI Safety, an OP grantee, generated global headlines with its statement calling AI extinction risk a top societal priority.
- •The report reflects on OP's evolving strategy and increasing measurable impact across global health, biosecurity, and AI safety focus areas.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| EA and Longtermist Wins and Losses | -- | 53.0 |
Cached Content Preview
HTTP 200Fetched Mar 20, 202668 KB
[Skip to Content](https://coefficientgiving.org/research/our-progress-in-2023-and-plans-for-2024/#content)
March 27, 2024
# Our Progress in 2023 and Plans for 2024
By
Alexander Berger
**_Editor’s note:_** _This article was published under our former name, Open Philanthropy. Some content may be outdated. You can see our latest writing [here](https://coefficientgiving.org/research-and-news)_ _._
Like many organizations, Open Philanthropy has had multiple founding moments. Depending on [how](https://coefficientgiving.org/research/the-open-philanthropy-project-is-now-an-independent-organization/) [you](https://blog.givewell.org/2014/08/20/open-philanthropy-project-formerly-givewell-labs/) [count](https://blog.givewell.org/2011/09/08/announcing-givewell-labs/), we will be either seven, ten, or thirteen years old this year. Regardless of when you start the clock, it’s possible that we’ve changed more in the last two years than over our full prior history. We’ve more than doubled the size of our team (to ~110), nearly doubled our annual giving (to >$750M), and [added](https://coefficientgiving.org/focus/global-aid-policy/) [five](https://coefficientgiving.org/focus/global-health-rd/) [new](https://coefficientgiving.org/focus/global-public-health-policy/) [program](https://coefficientgiving.org/focus/innovation-policy/) [areas](https://coefficientgiving.org/focus/ea-global-health-and-wellbeing/).
As our track record and volume of giving have grown, we are seeing more of our impact in the world. Across our focus areas, our funding played a (sometimes modest) role in some of 2023’s most important developments:
- We were among the supporters of the [clinical trials](https://openphilanthropy.org/grants/?q=malaria+vaccine+phase+III) that led to the World Health Organization (WHO) [officially recommending](https://www.who.int/news/item/02-10-2023-who-recommends-r21-matrix-m-vaccine-for-malaria-prevention-in-updated-advice-on-immunization) the R21 malaria vaccine. This is the second malaria vaccine recommended by WHO, which expects it to enable “sufficient vaccine supply to benefit all children living in areas where malaria is a public health risk.” Although the late-stage clinical trial funding was Open Philanthropy’s first involvement with R21 research, that isn’t the case for our new global health R&D program officer, [Katharine Collins](https://coefficientgiving.org/team/katharine-collins/), who invented R21 as a grad student.
- Our early commitment to AI safety has contributed to increased awareness of the associated risks and to early steps to reduce them. The Center for AI Safety, [one of our AI grantees](https://openphilanthropy.org/grants/center-for-ai-safety-general-support-2023/), made [headlines](https://coefficientgiving.org/wp-content/uploads/nytimes.com-AI-Poses-Risk-of-Extinction-Industry-Leaders-Warn.pdf) [across](https://www.independent.co.uk/space/rishi-sunak-san-francisco-siri-government-prime-minister-b2348994.html) the [globe](http
... (truncated, 68 KB total)Resource ID:
650e9fc73c334812 | Stable ID: ZjVhNDkyNj